Megan L Mckenney

Title: Megan L. Mckenney: Innovator in RET Kinase Inhibitors

Introduction

Megan L. Mckenney is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target RET kinase. Her work is crucial for advancing treatments for various RET-associated diseases and disorders.

Latest Patents

Mckenney holds a patent for "Fused heterocyclic compounds as RET kinase inhibitors." This patent includes compounds of the Formula (I) and their tautomers, stereoisomers, and pharmaceutically acceptable salts and solvates. These compounds are designed to inhibit RET kinase, providing potential therapeutic benefits in treating diseases associated with this target.

Career Highlights

Throughout her career, Mckenney has worked with notable companies such as Array Biopharma Inc. and Eli Lilly and Company. Her experience in these organizations has allowed her to collaborate with leading experts in the pharmaceutical industry, enhancing her research and development skills.

Collaborations

Mckenney has collaborated with esteemed colleagues, including James F. Blake and Donghua Dai. These partnerships have contributed to her innovative work and the advancement of her research in the field.

Conclusion

Megan L. Mckenney is a trailblazer in the development of RET kinase inhibitors, with a patent that showcases her innovative contributions to medicine. Her collaborations and career experiences reflect her commitment to advancing healthcare solutions.